Management Report as of December 31, 2025

The year 2025 was a year of growth, expansion, and strategic success for our company. Through targeted partnerships, the expansion of our service offerings, and the development of new markets, we were able to further strengthen our position.

In the past year 2025, Vitruvia Medical AG reported a profit after taxes of CHF 308,670.73 for the first time, compared to a loss of CHF 173,775.93 in the previous year.
Our subsidiary LT technologies GmbH & Co. KG generated revenue of EUR 2,540,929, compared to EUR 2,016,279 in the previous year, representing an increase of +26%. On a consolidated basis, earnings before interest, taxes, and amortization (EBITA) improved from EUR 178,398 to EUR 277,215 (a 55% increase compared to the previous year).

LT technologies GmbH & Co. KG, a wholly owned subsidiary of Vitruvia Medical AG, looks back on a strong 2025 and has outperformed expectations. The revenue and profit targets set for 2025 were more than met.

A significant milestone in July was the successful recertification under DIN EN ISO 13485:2021. This underscores the company's high quality standards and reliable process structure—a clear signal to customers, partners, and the market.

The collaboration with a German full-service provider has established itself as a sustainable partnership and is being continuously strengthened. A clear momentum is also evident on the customer side: revenue growth was achieved primarily with existing customers, who are increasingly relying on LT's cost-effective solutions—especially in light of the current financial challenges in the hospital sector.

This situation also presents opportunities: LT technologies GmbH & Co. KG's cost efficiency and service orientation come into play precisely where hospitals are forced to realize cost-saving potential—without compromising on quality or performance.

Another growth driver is the strengthened collaboration with an Austrian company, which already led to significant revenue increases in the first half of the year. The partnership is being strategically developed further to fully realize its long-term potential.

In the second half of 2025, revenue increased significantly through the acquisition of new customers, resulting in the annual target not only being met but actually exceeded.

Domestic business, in particular, benefited from newly acquired customers in the direct business segment and recorded a correspondingly positive trend. Furthermore, the signing of new contracts with a major German service provider set an important strategic course for 2026.

International business also performed well. Further improvement was achieved through the expansion into additional markets, particularly in Poland and the Czech Republic.

Looking ahead to 2026, we are planning additional measures to sustainably strengthen our growth. Already in the first quarter, we were able to increase revenue by approximately 10% compared to the same period last year—clear evidence of the positive business performance.

Vitruvia Medical AG
Board of Directors

Vitruvia AG - Kesselackerstrasse 18 - CH-5611 Anglikon - Tel. +41 44 915 33 78 - Mail: info@vitruvia-med.com - Web: www.vitruvia-med.com
Handelsregisteramt des Kantons Aargau - UID Nr. CHE-363.832.344
Luzerner Kantonalbank AG – CH-6002 Luzern - BIC: LUKBCH2260A - IBAN: CH07 0077 8220 8311 4200 1